Navigation Links
Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
Date:5/19/2011

SAN FRANCISCO and SEATTLE, May 19, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.  The preliminary data from the study HEP007 indicated that the risk of death for patients who received JX-594 at the high therapeutic dose was markedly reduced by more than 50 percent (hazard ratio < 0.5) when compared to patients randomized to a control low dose (one-tenth of the high dose). Clinical investigators enrolled approximately 30 patients at sites in the United States, Canada and South Korea.

The data were presented by David Kirn, M.D., president and chief executive officer of Jennerex, today in an oral presentation in the Presidential Symposium of the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Seattle, Washington.  These data were also chosen for inclusion in ASGCT's Media Event to be held during the annual meeting.  Jennerex and its partners expect to present further follow-up on the complete trial data set at a medical conference later this year.

A randomized, placebo-controlled Phase 2b clinical trial of JX-594 in patients with hepatocellular carcinoma (HCC) having failed sorafenib-(Nexavar®) treatment is planned for initiation in the second half of this year; this trial (TRAVERSE), conducted globally with Jennerex's partners, will evaluate survival in advanced HCC patients who have either progressed or exhibited intolerance after treatment with sorafenib, the current standard of care.

"We are extremely encouraged by the promising overall survival results presented today. These results are consistent with a clinically meaningful survival benefit in patients wit
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 New interactive ... innovative thought leaders of the medical device industry ... conference and expo, from June 18-20 in ... http://photos.prnewswire.com/prnh/20130517/613829 ) , These ... industry professionals practical presentations and implementable solutions on ...
(Date:5/17/2013)... SAN JOSE, Calif. , May 17, 2013 ... an agreement has been reached with ... entire portfolio of anti-infective human monoclonal antibody (mAb) ... six anti-infective human mAb products for treatment of ... strains of Staphylococcus aureus , Pseudomonas ...
(Date:5/17/2013)... 17, 2013 The paradigm of ‘one ... systems that can help predict the adverse and therapeutic ... Stepaniants, Head of Computational Biology at the Genomics Laboratory, ... to ensure high-quality genomics when used as part of ... to complex data sets to identify key clinical targets ...
(Date:5/17/2013)... IAC Industries wants to share with you the ... to set up and furnish a research lab knowing that ... a year’s time. How does a company make choices in ... What is efficient and cost-effective? , The solution was ... The planners at DisperSol determined that the concept of modular ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... STAAR Surgical Company,(Nasdaq: STAA ) today ... quarter and full year ended January 2, 2009 on ... The Company will host a conference call and webcast,on ... 1:30 p.m. Pacific to discuss,the Company,s fourth quarter and ...
... PARIS, March 4 , 2008 Key milestones, - ... programs:, - Recruitment of 311 samples achieved ... EHT 0202 in Alzheimer,s disease, - Expansion of the strategic collaboration ... 2008 Key events, - Appointment of a new Management Board, ...
... Berkeley, CA - As electronic circuits shrink from ... elusive proportions, researchers at the U.S. Department of ... Columbia University are studying how electrons flow through ... contacts gold atoms with a single molecule. Their ...
Cached Biology Technology:STAAR Surgical Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call 2ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 2ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 3ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 4ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 5ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 6ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 7ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 8ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 9ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 10ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 11Researchers discover a potential on-off switch for nanoelectronics 2Researchers discover a potential on-off switch for nanoelectronics 3Researchers discover a potential on-off switch for nanoelectronics 4
(Date:5/17/2013)... A new Dartmouth College study finds human-caused climate ... of tropical lizards, contradicting a host of recent ... rapidly warming planet. , The findings, which appear ... offer new hope for survival of a creature ... Most predictions that tropical cold-blooded animals, especially forest ...
(Date:5/16/2013)... Illustrating a commitment to the support of ... (AGA) Research Foundation has announced the inaugural AGA ... recipients. Supported by the National Institute of Diabetes ... award helps underrepresented minority students to further their ... , "By establishing this new award, AGA demonstrates ...
(Date:5/16/2013)... closer to a fast food restaurant had a higher ... away from fast food, according to researchers at The ... association was particularly strong among those with a lower ... the American Journal of Public Health indicates ... food restaurant, and among lower-income African-Americans, the density, or ...
Breaking Biology News(10 mins):Climate change may have little impact on tropical lizards 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3
... ANN ARBOR, Mich.---Brain implants that can more clearly ... created at the University of Michigan. The findings could ... such as Parkinson,s disease and paralysis. Neural electrodes ... years. When the electrodes are implanted, the brain first ...
... New research announced today, Wednesday 30th September, by a ... Synchrotron, Diamond Light Source, could have a significant impact ... control methods for worldwide agriculture. Published in the ... carried out by Dr Jing-Jiang Zhou and colleagues at ...
... -- Soybeans contain high levels of several ... These molecules can be used in the development ... and can be used in the treatment or ... (α, β, γ, and δ) of which γ-tocopherol ...
Cached Biology News:A step toward better brain implants using conducting polymer nanotubes 2A step toward better brain implants using conducting polymer nanotubes 3How the 100th protein structure solved at Diamond impacts our understanding of how insects smell 2How the 100th protein structure solved at Diamond impacts our understanding of how insects smell 3Eat soybeans to prevent diseases 2
... This microscope is described by end-users to ... incorporates the fundamentals of light microscopy and ... small footprint, it does not require much ... a busy lab environment. The DM-BA300 combines ...
... ergonomic microscopes are now available in digital ... DM-BA200 comes packed with Motic's patented Colour ... plug and play digital image capture head. ... a reversed quadruple nosepiece, deliver high quality ...
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... system combines the space and time dimensions of ... the optical microscope to open new horizons in ... source for excitation, the decay of a fluorescence ... the decay measured. Subtle changes in the ...
Biology Products: